| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| KRYS | KRYS | Shares | USD | XNGS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| KRYS | KRYS | Shares | USD | XNGS |
Krystal Biotech, Inc. develops and commercializes genetic medicines, focusing on severe, life-threatening, or rare diseases with limited treatment options. Its first product, VYJUVEK®, is a redosable gene therapy for dystrophic epidermolysis bullosa. The company utilizes a modified HSV-1 vector platform to create its therapies and operates two GMP manufacturing facilities. Krystal's pipeline includes various genetic therapies aimed at addressing the root causes of serious genetic disorders.
No recent RNS announcements for KRYS across KRYS.
No recent RNS announcements for KRYS across KRYS.